(Reuters) – Canada’s Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on Tuesday, helped by lower costs and strength in its Bausch and Lomb eyecare business, but its net loss widened and the company said it was feeling pricing pressure.